Seeking Alpha
18 Nov 2026, 06:15 UTC · 3h ago
Pfizer: Strong Growth Momentum And Attractive Valuation Support A Strong Buy
Impact · against what's priced in
Pfizer shows strong operational momentum with raised FY26 guidance and growth in new products, but much of this is already reflected in the current valuation. The stock's appeal rests more on a valuation rerating than on news that deviates from market expectations.
- PFE+0.40
No priced-in read yet
- In context
Pfizer's raised FY26 revenue guidance to $62B–$64B and a 32% growth rate in launched and acquired products demonstrate strong momentum. However, the stock's low 9.6x multiple suggests the market remains cautious regarding legacy drug pricing and market share losses.
Read from the article alone

Top 2 movers · tap to explore




